RxDoctor Payments DataLook up a doctor →

Ramon Rodriguez Cruz, MD

Neurology · Orlando, FLNPI 1255377099

Payments from drug & device makers

$3,444,306in general payments, 2019–2025

Across 2,251 payments — averaging $1530.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • Genentech, Inc.$768K
  • AbbVie$430K
  • Eisai Inc.$229K
  • Neurocrine Biosciences, Inc.$196K
  • Acorda Therapeutics, Inc$144K
  • plus $584K from 53 others
$786,987in research payments, 2019–2025

Across 15 payments — averaging $52,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$555K
  • Amneal Pharmaceuticals LLC$231K
  • Neurocrine Biosciences, Inc.$870

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly11$1,094,022
Genentech, Inc.79$767,862
AbbVie(2 entities)466$430,060
Eisai Inc.161$228,533
Neurocrine Biosciences, Inc.290$195,768
Acorda Therapeutics, Inc154$144,325
Sage Therapeutics, LLC6$140,235
Teva Pharmaceuticals USA, Inc.156$134,580
Amneal Pharmaceuticals LLC101$94,296
MDD US Operations, LLC155$45,289
Adamas Pharmaceuticals, Inc.57$40,486
Sunovion Pharmaceuticals Inc.42$22,386
Acadia Pharmaceuticals Inc39$21,373
Boston Scientific39$19,465
Kyowa Kirin, Inc.44$16,666
Tanabe Pharma America, Inc.32$16,234
Merz Pharmaceuticals, LLC24$12,983
Abbott17$6,437
Avion Pharmaceuticals8$6,184
Lilly USA, LLC50$961
Pfizer59$749
GE HealthCare23$557
Biogen18$445
Amgen24$410
Argenx US, Inc.28$391
Biohaven Pharmaceutical Holding Company Ltd.24$377
Supernus Pharmaceuticals, Inc.28$320
Biohaven Pharmaceuticals, Inc.20$286
UCB, Inc.13$284
EMD Serono, Inc.2$246
Otsuka America Pharmaceutical, Inc.11$237
Medtronic3$203
CSL Behring6$178
Lundbeck LLC6$124
Idorsia Pharmaceuticals US Inc2$122
GRT US Holding, Inc.3$117
Takeda Pharmaceuticals U.S.A., Inc.4$94
Grifols USA, LLC5$93
Currax Pharmaceuticals LLC6$82
Dynasplint Systems Inc.1$76
Neuronetics, Inc.1$68
Corium, LLC4$64
Revance Therapeutics, Inc.2$56
Alnylam Pharmaceuticals Inc.2$55
Novartis4$53
AstraZeneca2$52
Livanova USA, Inc.2$48
C2n Diagnostics, LLC2$47
Cala Health, Inc.2$45
Microtransponder, Inc.1$43
Vertical Pharmaceuticals, LLC2$37
Impel Pharmaceuticals LLC2$35
Johnson & Johnson(2 entities)2$34
Genentech USA, Inc.1$28
Merz North America, Inc.1$24
Hoffmann-la Roche Limited1$24
Catalyst Pharmaceuticals, Inc.1$21
Scilex Pharmaceuticals Inc.1$19
Azurity Pharmaceuticals, Inc.1$17

How this compares

$3,444,306 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$864,589
Medicare patients
697
Services billed
50,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Orlando

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →